Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders.
Invasive fungal infections contribute to the morbidity and mortality of immunosuppressed patients treated for hematologic malignancy and those undergoing hematopoietic cell transplantation. After years of limited advances, the management of fungal infections in these patients is now rapidly evolving. In this update, we will outline changes in the epidemiology of invasive fungal infections, discuss current issues in diagnosis and susceptibility testing, and review the current classes of antifungal drugs, focusing on newly licensed therapies. Data on antifungal prophylaxis, empiric therapy, and treatment of documented invasive fungal infections including single agents and combinations with newly licensed agents will be reviewed with emphasis on their impact on patients with hematologic malignancies.
Hayes-Lattin
Brandon
B
Adult Bone Marrow Transplant Program, Division of Hematology and Medical Oncology, Oregon Health and Science University, OHSU Cancer Institute, Portland, OR, USA. hayeslat@ohsu.edu
Maziarz
Richard T
RT
D000935:Antifungal Agents / Q000145:classification / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D009894:Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology; D016896:Treatment Outcome
D000935:Antifungal Agents